NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Applied BioPhysics, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Applied BioPhysics Announces New IBIDI Slides - Expands Research Capability - Applied BioPhysics, Inc. announces the release of its new Ibidi product lines -- wounding inserts, angiogenesis slides and high capacity dishes
Applied BioPhysics Announces New IBIDI Slides - Expands Research Capability

 

NewswireTODAY - /newswire/ - Troy, NY, United States, 2009/03/26 - Applied BioPhysics, Inc. announces the release of its new Ibidi product lines -- wounding inserts, angiogenesis slides and high capacity dishes.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The ibidi product family comprises a variety of different shapes of ì-Slides, ì-Dishes and plates which all have been designed for high-end microscopic analysis of fixed or living cells. The high optical quality of the material is similar to that of glass, so you can perform all kinds of fluorescence experiments with uncompromised resolution and choice of wavelength.

Ibidi’s new wounding inserts are ideal for cell migration or cell invasion studies. They are more effective than the traditional scrape method because they leave a well-defined cell free gap. The inserts can be inserted into any bio-compatible surface and used to culture one or multiple cell lines. These inserts have two wells that create 2 distinct cell patches with a defined gap of 400µm. The small capacity (70ul) requires only a small number of cells and when the insert is removed it leaves NO RESIDUE and the protein layer stays intact.

Ibidi’s new Angiogenesis slides are an advanced slide for producing 3D gel matrices that provide a flat surface for improved visual focus, while minimizing the use of expensive reagents. The Angiogenesis slide has a “well within a well” design perfect for angiogenesis studies. Each slide has 15 wells with 50µl capacity with smaller 10µl capacity wells inside. The small inside well allows matrigel to set without meniscus formation.

Ibidi’s new HIGH capacity dishes now have a 2mL capacity, double the capacity of the LOW dishes. Ibidi µdishes have a special locking feature for long term studies with no evaporation. They are available with a grid or culture insert option.

Applied BioPhysics, Inc. (biophysics.com), manufacturer of the analytical instrument ECIS (Electric Cell substrate Impedance Sensing), is an official distributor of IBIDI Products.

For more information on ibidi slides and applications please visit our website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Applied BioPhysics, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Applied BioPhysics Announces New IBIDI Slides - Expands Research Capability

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Catherine Toniatti - BioPhysics.com 
518-880-6860 ctoniatti[.]biophysics.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Applied BioPhysics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Applied BioPhysics, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)